MediCool Technologies Welcomes New CEO to Lead Development of Novel AFib Therapy
Electrophysiology Industry Veteran to Lead Early Stage Commercialization
MediCool Technologies, an early stage medical device company developing a novel device to painlessly terminate cardiac arrhythmias, today announced that the Company has appointed Mr. Jeff Rynbrandt as President and Chief Executive Officer.
Mr. Rynbrandt brings to the Company 25 year’s leadership across multiple disciplines in both commercial and military service, including over 18 years of experience in both Cardiac Rhythm Management and Electrophysiology. Most recent position he served as Vice President of Sales for CardioFocus, a novel startup company providing a laser ablation solution for patients with atrial fibrillation, where he that developed and implemented a commercialization strategy for the United States which began commercialization of the CardioFocus solution. Previously, he worked for 15 years at Boston Scientific, one of the three leading cardiac device companies in the world. At Boston Scientific, he led sales regions across the mid-Atlantic, was responsible for launching new and novel technologies, such as the Sub-Cutaneous Implantable Cardioverter Defibrillator and the Rhythmia Mapping System, and served in numerous roles including the field as a sales representative, clinical representative and finally a sales manager of multiple regions and business units.
He graduated from the United States Military Academy at West Point with a Bachelor’s of Science in 1993 and after completing service went on to receive an MBA in Supply Chain Management and Finance in 2002.
“We are excited to have someone with Jeff’s experience in the medical device industry lead our team and help advance our proprietary therapy for the millions of AF patients worldwide” stated Mr. Rich Sanders, who will transition from CEO to Chairman of the Board. “This new technology represents a novel way to painlessly terminate atrial fibrillation, and shows tremendous promise based on our published preclinical work” notes Dr. Paul Friedman, MD, FHRS, and Chief Technology Officer. According to Samuel Asirvatham, MD, FHRS, and Chief Medical Officer, “the advances this technology represents will benefit large numbers of patients who are either not candidates for current approaches to treating Atrial Fibrillation, or who need a better approach than traditional ablation or pharmacologic therapy.”
In his new role, Mr. Rynbrandt will be responsible for completing critical research under the SBIR award, and raising funding to begin the early stage commercialization of this novel technology.
See Full Press Release at the Source: MediCool Technologies welcomes new CEO to lead development of novel A-F therapy
Press Release by Medicool Technologies
Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.